A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

• Autors principals: Fabian Lang (Autor), Lydia Wunderle (Autor), Susanne Badura (Autor), Eberhard Schleyer (Autor), Monika Brüggemann (Autor), Hubert Serve (Autor), Susanne Schnittger (Autor), Nicola Gökbuget (Autor), Heike Pfeifer (Autor), Sebastian Wagner (Autor), Kevin Ashelford (Autor), Gesine Bug (Autor), Oliver G. Ottmann (Autor)
• Format: Llibre
• Publicat: BMC, 2020-09-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Abstract Background Combined inhibition of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) complexes may be an efficient treatment for acute leukemia. The primary objective of this phase I single center open label study was to determine the maximum tolerated dose (M...